Cancer Drug Futures Analysed in New In-demand Market Reports Available at MarketPublishers.com

LONDON--(BUSINESS WIRE)-- Market Publishers Ltd informs that new in-demand reports on cancer drugs markets by Espicom have been added to its catalogue.

Lung Cancer Drug Futures. The lung cancer market is set for radical change. Many current first-line therapies will become subject to generic competition. In 2007, chemotherapy treatments accounted for 68% of the market this figure falling to 32% by 2014; targeted treatments are forecast to increase to 60%. This all-covering and comprehensive report offers a deep review and analysis of the market and its future … http://marketpublishers.com/r/L1A038CE0E4EN.html

Breast Cancer Drug Futures. Breast cancer is the second most common cause of death from cancer in women. The breast cancer market is steadily growing due to effective treatments. Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in Japan. This study is a valuable guide into the future of the market and its performance … http://marketpublishers.com/r/BA82292AE57EN.html

Colorectal Cancer Drug Futures. Only around 40% of CRCs are found at early stage, there remains considerable unmet clinical need within the CRC market. In 2008, the CRC drug market was valued at just over US$8 billion. The future outlooks for the market, its major trends and developments, challenges and risks are thoroughly discussed and analysed in the present study … http://marketpublishers.com/r/CB79BD7FA04EN.html

Prostate Cancer Drug Futures. The PC market was estimated to be worth US$5.2 billion in 2008. It is currently driven by the use of hormonal therapies prescribed for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years. This report provides a deep insight into the market delving into an exhaustive analysis of its prospects, developments, future trends … http://marketpublishers.com/r/P3DCC66A6CFEN.html

Renal Cell Carcimona Cancer Drug Futures. The number of renal cell carcinoma patients by value, in the US, Europe and Japan will increase by 35.7% by 2015. The total RCC sales for branded products will increase substantially from almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%. This study provides a detailed overview of the market offering insightful data and an exhaustive outlook analysis … http://marketpublishers.com/r/R3AC1F884B0EN.html

More new reports by Espicom can be found at http://marketpublishers.com/members/espicom/info.html



CONTACT:

TD The Market Publishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 123 2220
Fax: +44 207 900 3970
[email protected]
www.marketpublishers.com

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.